TEXT

Introduction
Idiopathic orbital inflammatory syndrome (IOIS), also known as orbital pseudotumour is a heterogeneous group of disorders characterized by orbital inflammation without identifiable local or systemic causes. It is a rare clinical entity and a diagnosis of exclusion. [1] There have been various classification systems proposed however due to the highly variable clinical and pathological features of IOIS none are universally accepted and used. [2] [3] [4] IOIS can affect any structure in the orbit and the presentation can range from abrupt to insidious onset. Although IOIS is typically steroid responsive, it is a difficult condition to treat with many patients requiring multiple systemic immunosuppressant drugs and radiotherapy. Disease relapse is common.
The diagnosis of IOIS is often made on the basis of the clinical response to systemic corticosteroids. Significantly many different orbital lesions, including thyroid eye disease and malignancy, may respond to corticosteroids and therefore a histological diagnosis is considered important by most clinicians. The aim of this study was to characterize the clinical features, histopathology and treatment outcomes in patients with biopsy proven IOIS.
Material and Methods
The medical records of 98 patients with clinical diagnosis of IOIS or orbital pseudotumour diagnosed at the Sydney Eye Hospital between 1995 and 2005 were reviewed. The inclusion criteria included a confirmed histopathological diagnosis of IOIS and a minimum follow up of 6 months to observe response to treatment. Seventy four patients with diagnosis of IOIS but without a confirmed histopathological diagnosis were excluded from the review. Twenty four patients had biopsy proven IOIS and all of them met the minimum follow up requirements. Approval for the study was obtained from the Sydney Eastern Sydney Illawarra Area Health Service (SESIAHS) Human Research and Ethics Committee.
The data extracted included age, gender, country of birth, signs and symptoms, surgical and radiological features, histopathological features, clinical course, treatment regimen and outcome. Follow-up information was collected from individual treating ophthalmologists. Due to the variable amount of follow up, outcome measures in terms of relapses, were reported as incidence rates (i.e. relapse / person-years of follow up). [5] Clinical course was correlated with histopathology to delineate appropriate treatment regimens and prognosis. Statistical analyses were performed by using SAS version 9 software (SAS Institute, Cary, North Carolina, USA).
Results
The 24 patients ranged in age from 14 to 75 years (mean 45.2 years); 14 were male and 10 were female. The left eye was affected in 13 patients, right eye in 10 patients and both eyes in one patient.
The median duration of symptoms prior to presentation was 4 weeks (range 0.3 weeks to 12 weeks). The patients presented with a range of signs and symptoms. A swelling/mass was the most common presentation followed by proptosis, pain, extraocular muscle restriction, diplopia, ptosis and decreased vision. Table 1 summarises the clinical signs and symptoms at presentation. Anatomically orbital fat was the most commonly involved orbital structure followed by lacrimal gland and extraocular muscle. 1 one patient had eyelid mass and one patient had a medial canthal mass Histopathology The classification system described by Mombaerts has been used in the current study as it is widely accepted for classifying IOIS. [2] In nine of the patients the cellular infiltrate, the stromal component and the vascular changes were consistent with 'classical orbital pseudotumour' (Figure1). This cellular infiltrate consisted of inflammatory cells, mainly of mature lymphocytes, admixed with plasma cells, neutrophils, eosinophils and occasionally macrophages and histiocytes. Consistent with classical orbital pseudotumour there was an increase in the amount of connective tissue with variable amounts of tissue edema and fibrosis. There was a mixture of chronic inflammatory cells surrounding the blood vessels. In 13 of the 24 cases the diagnosis was that of 'idiopathic sclerosing orbital inflammation'. In these patients connective tissue sclerosis and hyalinization predominated with a paucity of inflammatory cells (Figure2). In one patient the histopathological features were consistent with a 'granulomatous orbital pseudotumour' with lesion characterised by histiocytic infiltration and multinucleated giant cells. In one case the histology revealed a 'vasculitic orbital pseudotumour' with a vasculitis of the small blood vessels the defining feature. Four patients who had been initially diagnosed with classical orbital pseudotumour later developed the sclerosing subtype. One patient developed a retrobulbar haemorrhage after biopsy and one further patient had a CSF leak following orbital decompression and biopsy which subsequently required surgical repair.
Therapy consisted of observation alone, antibiotics, oral corticosteroids, intravenous corticosteroids and systemic immunosuppressive drugs. In a majority of the patients oral steroids (19/24) were the initial treatment and doses ranged from 50-100mg/day. Seven patients required treatment with additional immunosuppressant drugs to control the inflammatory process. The drugs used included methotrexate, azathioprine, mycophenolate and cyclosporin. In five patients there was resolution of the signs and symptoms without treatment and in half of the patients the disease process was brought under control with the use of one medication. Nearly a third of the patients (7/24) needed two or more medications to bring the disease into remission (Tables 4 and 5 The follow-up period was variable with a range of 6 to 120 months (median 23 months). 10 patients suffered relapses within the follow up period. The rate of relapse was 0.18/person-year. Surprisingly the relapse rate for those with classical orbital pseudotumour was 0.29/person-year and for those with sclerosing orbital pseudotumour was 0.15/person-year. The patients with granulomatous pseudotumour and vasculitic pseudotumour had no relapses during their follow-up period.
Two thirds of the patients (16/24) had complete resolution of their signs and symptoms; 6/9 (67%) of those diagnosed with classical pseudotumour and 8/13 (62%) diagnosed with sclerosing orbital pseudotumour. There was partial resolution of signs/symptoms in 17% of patients (4/24) whilst 17% (4/24) patients had no improvement in their symptoms/signs.
Discussion
Idiopathic Orbital Inflammatory Syndrome is a diagnosis that is made following careful investigations to exclude common orbital tumors, thyroid eye disease and systemic causes of inflammatory mass lesions. [6] IOIS accounts for approximately 10% of all orbital "tumors". [7, 8] It is likely that the etiology in IOIS is autoimmune in origin with viral, genetic and environmental factors proposed as possible trigger factors. [1, 2, [9] [10] [11] The current study confirms that IOIS can present with a range of clinical manifestations, is typically unilateral developing over days to weeks, and has no gender, age or racial predilection in the Australian population. There is a mixture of infiltrative and inflammatory signs and symptoms including: swelling, pain, proptosis, extraocular muscle restriction, diplopia, decreased vision and ptosis. Any orbital structure can be involved either focally or in a diffuse manner, with orbital fat, lacrimal gland and the extraocular muscles the common sites of involvement. Relapses are common during the course of the disease.
IOIS is often diagnosed on the basis of a rapid response to a trial of systemic corticosteroid treatment, as was the case in the 74 patients originally considered for inclusion in the study. [12] A rapid response to corticosteroids, although a useful diagnostic indicator, is not diagnostic. A number of studies have reported steroid unresponsive idiopathic inflammatory orbital tumors, and thyroid eye disease and malignant eye disease may respond to steroid therapy initially. [2] It is recommended that a biopsy be performed to confirm the diagnosis of IOIS, except in the case of pure myositic locations and posteriorly located tumours where there is a significant risk of damage to the optic nerve. [2] We included only biopsy proven cases in this study to correlate clinical and pathological features. It is not possible to identify the indications for biopsy in the group of patients initially considered for inclusion in the study. It is tempting to speculate that patients who underwent biopsy were those with either severe or atypical clinical features.
Initial investigation should include a careful history and complete physical examination followed by full blood count, ESR, CRP and radiology with a CT and/or MRI scan of the affected orbit. Further investigation depends on the individual clinical features. The indications for treatment of IOIS are threat to vision, pain or loss of function. There is often good resolution of signs and symptoms with steroid therapy. [13] Additional immunosuppressant drugs and or radiotherapy are necessary when the response to steroids is unsatisfactory. [1, 14] IOIS can be difficult to manage with approximately a third of the patient needing two or more immunosuppressant drugs to control disease. Immunosuppressant drugs found to be effective in the treatment of IOIS include: azathioprine, methotrexate, mycophenolate and cyclosporin. There is no consensus on treatment protocol and choice of therapy needs to be individualized by ophthalmologists and physicians with experience in using these drugs in ocular inflammatory disease. [15] There is no agreement regarding a histopathological classification for IOIS. Some consider sclerosing orbital pseudotumour a distinct clinicopathological entity that may be related to systemic fibrotic disorders such as retroperitoneal fibrosis. [6, [15] [16] [17] [18] [19] Others aver that whilst classical orbital pseudotumour lesions demonstrates a fibroinflammatory infiltrate, lesions with atypical histopathological patterns such as extensive sclerosis, vasculitis, granulomatous inflammation and tissue eosinophilia represent subgroups within the umbrella diagnosis of IOIS. [2, 20] In keeping with this view, three patients in this study who had been initially diagnosed with classical orbital pseudotumour later went onto to develop sclerosing orbital pseudotumour. Whether sclerosing orbital pseudotumour is a separate clinical entity or represents a "healing phase" of IOIS or is part of a systemic disease process, remains to be elucidated. This distinction is important for the clinician as the disease progression, prognosis and treatment modalities may be different depending on the histopathological diagnosis.
The present studies findings are not consistent with the view that sclerosing and vasculitic orbital pseudotumours exhibit aggressive behaviour and have poorer prognosis. In this case series, the rate of relapses amongst classical orbital pseudotumour was 0.29/person-year follow-up and this was higher than those with sclerosing orbital pseudotumour (0.15/person-year of follow-up). Additionally, clinical resolution was achieved in two thirds of the patients regardless of the histopathological classification.
This study has a number of significant limitations as it was a small retrospective case series. The patients were selected from a tertiary referral hospital with resultant selection bias. Further, three fourths of the patients initially considered for inclusion in the study did not have a biopsy to confirm the diagnosis and were excluded. It is likely that the patients who had a biopsy were patients with atypical or severe clinical features and this may introduce a bias to the study population. The results of the study need to be interpreted with caution given its retrospective design and the multiple potential types of bias inherent in such studies. The larger prospective study required to characterize the clinical and histopathological patterns involved in IOIS would be extremely difficult to perform and management decisions continue to rely on data from small selective studies such as ours. The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted)to be published in BJO editions and any other BMJPGL products to exploit all subsidiary rights, as set out in our licence (http://bjo.bmjjournals.com/ifora/licence.pdf)."
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